BY AND AMONG ACTINIUM PHARMACEUTICALS, INC. AND THE INVESTORS PARTY HERETO October __, 2012Unit Investor Rights Agreement • January 4th, 2013 • Cactus Ventures, Inc. • Blank checks • New York
THIS 2012 UNIT INVESTOR RIGHTS AGREEMENT (the “Agreement”) is entered into as of October__, 2012, by and among Actinium Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the persons identified on Exhibit A hereto (the “Investors”), and the Placement Agent (defined below).
Project Agreement Number: 1 Aptiv Project Number: ACTI-1903Project Agreement • January 4th, 2013 • Cactus Ventures, Inc. • Blank checks
This Project Agreement is made and entered into on September 30, 2011, the Effective Date, by and between Actinium Pharmaceuticals, Inc., with offices at 391 Lafayette Street, Newark, NJ 07105 (hereinafter referred to as "Client") and Aptiv Solutions, Inc., together with its Affiliates, with offices at 1925 Isaac Newton Square, Suite 100, Reston, Virginia 20190 (hereinafter referred to as "Aptiv").
CLINICAL TRIAL AGREEMENTClinical Trial Agreement • January 4th, 2013 • Cactus Ventures, Inc. • Blank checks
THIS CLINICAL TRIAL AGREEMENT ("Agreement") is made by and between Fred Hutchinson Cancer Research Center, a nonprofit corporation having a principal place of business at 1100 Fairview Avenue N., J5-110, Seattle, Washington 98109 ("Site") and Actinium Pharmaceuticals, Inc. with an address of 25B Hanover Road, Florham Park, New Jersey 07932 ("Actinium"). This Agreement is entered into this July 19, 2012.
LICENSE AGREEMENTLicense Agreement • January 4th, 2013 • Cactus Ventures, Inc. • Blank checks • Washington
This License Agreement (the "Agreement") effective as of the Effective Date, by and between Fred Hutchinson Cancer Research Center, a research institution organized as a nonprofit corporation under the laws of the state of Washington, having its principal offices at 1100 Fairview Avenue North, Seattle, Washington 98108, USA ("FHCRC") and Actinium Pharmaceuticals, Inc., a Delaware corporation, with principal offices at 391 Lafayette Street, Newark, NJ 07105 ("Company").
CLINICAL TRIAL AGREEMENT (SK#11731)Clinical Trial Agreement • January 4th, 2013 • Cactus Ventures, Inc. • Blank checks • New York
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH and its affiliate MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES both having a principal place of business at 1275 York Avenue, New York, New York 10021, membership corporations of the State of New York (hereinafter "SKI/MEMORIAL"), and
CLINICAL TRIAL AGREEMENTClinical Trial Agreement • January 4th, 2013 • Cactus Ventures, Inc. • Blank checks • Maryland
THIS CLINICAL TRIAL AGREEIVIENT ("Agreement") is made by and between Johns Hopkins University, having a School of Medicine with an Office of Research Administration located at 733 North Broadway, Suite 117, Baltimore, Maryland 21205 ("Site") and Actinium Pharmaceuticals, Inc, with an address of 501 Fifth Avenue, rt Floor, New York, NY 10017 ("Actinium"). This Agreement is entered into as of the last signature (the "Effective Date").
AMENDMENT No. 1 TO REGISTRATION RIGHTS AGREEMENT AMONG ACTINIUM PHARMACEUTICALS, INC., ACTINIUM HOLDINGS LIMITED (FORMERLY GENERAL ATLANTIC INVESTMENTS LIMITED) AND CERTAIN STOCKHOLDERS, DATED JUNE 30, 2000Registration Rights Agreement • January 4th, 2013 • Cactus Ventures, Inc. • Blank checks
THIS AMENDMENT No. 1 ("Amendment No.1") to the REGISTRATION RIGHTS AGREEMENT among ACTINIUM PHARMACEUTICALS, INC. ("API"), ACTINIUM HOLDINGS LIMITED("AHL") and certain STOCKHOLDERS of API, dated June 30, 2000 ("Agreement"), is made and entered into as of September 29, 2011 ("Effective Date") by and among API, AHL and the Stockholders of API who are signatories to this Amendment No. 1, all collectively referred to herein as the "parties," with each being a "party." Capitalized terms not otherwise defined herein shall have the same meaning ascribed to such terms in the Agreement.
CLINICAL TRIAL AGREEMENTClinical Trial Agreement • January 4th, 2013 • Cactus Ventures, Inc. • Blank checks
THIS CLINICAL TRIAL AGREEMENT ("Agreement") is made by and between The Trustees of the University of Pennsylvania, a nonprofit corporation having a business address at 3451 Walnut Street, Rm. P-221 Franklin Building, Philadelphia, Pa 19104 ("Site") and Actinium Pharmaceuticals, Inc. with an address of 391 Lafayette Street, Newark, New Jersey 07105 ("Actinium"). This Agreement is entered into on the date of last signature.
CLINICAL TRIAL AGREEMENTClinical Trial Agreement • January 4th, 2013 • Cactus Ventures, Inc. • Blank checks • New York
THIS AGREEMENT is made and entered into by and between SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH and its affiliate MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES both having a principal place of business at 1275 York Avenue, New York, New York 10065, membership corporations of the State of New York (hereinafter " SKI/MEMORIAL"), and ACTINIUM PHARMACEUTICAL INC., a corporation having its principal place of business at 391 Lafayette Street, Newark, NJ 07105 (hereinafter "COMPANY"). This Agreement is effective as of the date of the last party to subscribe below (hereinafter "Effective Date").
Re: Waiver of Registration RightsWaiver of Registration Rights • January 4th, 2013 • Cactus Ventures, Inc. • Blank checks
SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT BY AND AMONG ACTINIUM PHARMACEUTICALS, INC. ACTINIUM HOLDINGS LIMITED AND THE INVESTORS PARTY HERETO October 5, 2011Investor Rights Agreement • January 4th, 2013 • Cactus Ventures, Inc. • Blank checks • New York
REGISTRATION RIGHTS AGREEMENT among ACTINIUM PHARMACEUTICALS, INC., GENERAL ATLANTIC INVESTMENTS LIMITED, N.V. ORGANON, ISOTOPIA B.V. DR. MAURITS W. GEERLINGS, SR., DR. MAURITS W. GEERLINGS, JR. and KENNETH R. GIVENS Dated: June __, 2000Registration Rights Agreement • January 4th, 2013 • Cactus Ventures, Inc. • Blank checks • New York
REGISTRATION RIGHTS AGREEMENT, dated [ ], 2000 (this "Agreement"), among ACTINIUM PHARMACEUTICALS, INC., a Delaware corporation (the "Company"), GENERAL ATLANTIC INVESTMENTS LIMITED, a Bermuda corporation ("General Atlantic"), N.V. ORGANON, a Netherlands corporation, ISOTOPIA B.V., a private limited company established under Netherlands law ("Isotopia"), DR. MAURITS W. GEERLINGS, SR., DR. MAURITS W. GEERLINGS, JR. and KENNETH R. GIVENS.
FIRST AMENDED AND RESTATED STOCKHOLDERS AGREEMENT AMONG ACTINIUM PHARMACEUTICALS, INC., ACTINIUM HOLDINGS LIMITED (FORMERLY GENERAL ATLANTIC INVESTMENTS LIMITED), AND THE STOCKHOLDERS LISTED ON SCHEDULE A HERETO Dated: October 5, 2011Stockholders Agreement • January 4th, 2013 • Cactus Ventures, Inc. • Blank checks • New York
WHEREAS, the Company, Actinium Pharmaceuticals, Ltd., a Bermuda corporation (the "Actinium Bermuda"), and the Existing Stockholders are parties to that certain Stockholders Agreement dated as of June 30, 2000 (the "Prior Stockholders Agreement");
July , 2011Waiver of Anti-Dilution Rights, New Issuance Notice and Notice of Exercise of Preemptive Rights • January 4th, 2013 • Cactus Ventures, Inc. • Blank checks
Reference is made to that certain Stockholders Agreement by and among Actinium Pharmaceuticals, Inc. (the "Company"), Actinium Pharmaceuticals, Ltd., Actinium Holdings Limited ("AHL" and formerly named General Atlantic Investments Limited) and the Stockholders listed on Schedule A thereto, dated June 30, 2000 (the "Stockholders Agreement"). Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Stockholders Agreement. The Company intends to sell up to 27,586,207 shares of Series E Convertible Preferred Stock (the "New Securities") pursuant to a draft Series E Preferred Stock Purchase Agreement (the "Purchase Agreement") by and among the Company and the Purchasers identified on Exhibit A thereto (the "Sale").
ContractResearch Agreement • January 4th, 2013 • Cactus Ventures, Inc. • Blank checks
Actinium Pharmaceuticals, Inc.Forbearance Agreement • January 4th, 2013 • Cactus Ventures, Inc. • Blank checks
Following up on our recent discussions I am writing to confirm the agreement between Sloan-Kettering Institute for Cancer Research (SKI) and Actinium Pharmaceutical, Inc. (API) as follows:
CLINICAL TRIAL AGREEMENTClinical Trial Agreement • January 4th, 2013 • Cactus Ventures, Inc. • Blank checks
THIS CLINICAL TRIAL AGREEMENT ("Agreement") is made by and between The University of Texas M.D. Anderson Cancer Center, a member institution of The University of Texas System " system" having a principal place of business at 1515 Holcombe Blvd. Houston, TX 77030 ("Site") and Actinium Pharmaceuticals, Inc. with an address of 391 Lafayette Street, Newark, New Jersey 07105 ("Actinium"). This Agreement is entered into this 6th day of August 2012.
LAIDLAW & COMPANY (UK) LTD. * Member FINRA, SIPC* *Incorporated in England & Wales: Company No. 3870324* *Authorized and Regulated by the Financial Services Authority *Engagement Agreement • January 4th, 2013 • Cactus Ventures, Inc. • Blank checks • New York
Pursuant to this exclusive ENGAGEMENT AGREEMENT (the "Agreement") by and between Laidlaw & Company (UK) Ltd., a United Kingdom corporation with offices at 90 Park Avenue, New York, New York 10016 ("Laidlaw") and Actinium Pharmaceuticals Inc. (the "Client", "API" or the "Company"), Laidlaw is engaged by the Client to perform the services (the "Services") agreed to hereby on the terms set forth herein.
EMPLOYMENT AGREEMENTEmployment Agreement • January 4th, 2013 • Cactus Ventures, Inc. • Blank checks • Delaware
EMPLOYMENT AGREEMENT dated as of January 2, 2006 by and between Actinium Pharmaceuticals Inc., a Delaware corporation (the "Company"), and Dragan Cicic, M.D. (the "Executive ").
